TTRX:NASDAQTurn Therapeutics Inc. Analysis
Data as of 2026-08-31 - not real-time
$9.72
Latest Price
9/10Risk
Risk Level: High
Executive Summary
Turn Therapeutics Inc. trades at $9.72, with its short-term moving averages stacked above the longer-term ones — a bullish trend structure. Across the trailing 30 sessions it lost 3.3%. With RSI at 53.5 the momentum picture is neutral, alongside a bearish MACD signal. Price has been bracketed by support at $8.58 and resistance at $10.95.
The company is not currently profitable on a trailing basis, so earnings multiples offer no valuation support. The average analyst target implies 167.5% above today's level.
Risk comes out at 9 of a possible 10, a high reading. With 30-day volatility of 80.3%, a beta of 1.53 and a maximum drawdown of 70.5%, position sizing matters more than entry timing here. Thin trading volumes mean execution costs can be material on larger orders. The wider market backdrop reads extreme greed at 94 on the fear-greed composite.
Across every horizon the signals point the same way: hold, at a conviction of 1 out of 10.
The company is not currently profitable on a trailing basis, so earnings multiples offer no valuation support. The average analyst target implies 167.5% above today's level.
Risk comes out at 9 of a possible 10, a high reading. With 30-day volatility of 80.3%, a beta of 1.53 and a maximum drawdown of 70.5%, position sizing matters more than entry timing here. Thin trading volumes mean execution costs can be material on larger orders. The wider market backdrop reads extreme greed at 94 on the fear-greed composite.
Across every horizon the signals point the same way: hold, at a conviction of 1 out of 10.
Top Market Events
18dTurn Therapeutics Provides Corporate Updates and Reports Second Quarter 2026 Financial ResultsTurn Therapeutics Inc.Morningstar%2c Inc.18dTurn Therapeutics Provides Corporate Updates and Reports Second Quarter 2026 Financial...Nasdaq18dTurn Therapeutics Provides Corporate Updates and Reports Second Quarter 2026 Financial ResultsThis press...
Market Outlook
Short Term
< 1 yearNeutral
Model confidence: 1/10
Key Factors
- Short-term moving averages stacked above long-term ones
- Trading above the 200-day average of 5.20
- MACD momentum is negative
Medium Term
1–3 yearsNeutral
Model confidence: 1/10
Key Factors
- Short-term moving averages stacked above long-term ones
- Trading above the 200-day average of 5.20
- Analyst targets imply +167.5% versus the current price
Long Term
> 3 yearsNeutral
Model confidence: 1/10
Key Factors
- Analyst targets imply +167.5% versus the current price
- Negative return on equity of -686.3%
- Elevated debt-to-equity of 891
Key Metrics & Analysis
Financial Health
P/E Ratio-64.8
ROE-686.28%
ROA-50.27%
Debt/Equity891.13
P/B Ratio422.6
Op. Cash Flow$-4321048
Free Cash Flow$4.2M
Industry P/E30.2
Technical Analysis
TrendBullish
RSI53.5
Support$8.58
Resistance$10.95
MA 20$9.81
MA 50$8.88
MA 200$5.20
MACDBearish
VolumeDecreasing
Fear & Greed Index94
Valuation
Fair Value$1.90
Target Price$26.00
Upside/Downside167.49%
GradeFair
TypeGrowth
Risk Assessment
Beta1.53
Volatility80.33%
Sector RiskMedium
Reg. RiskHigh
Geo RiskLow
Currency RiskLow
Liquidity RiskHigh
Similar Tickers
This analysis may contain inaccuracies and is provided for informational and research purposes only. It is not personal investment advice, a recommendation, or an instruction to buy, sell, or hold any asset.